I farmaci antitrombotici in gravidanza.

Translated title of the contribution: Antithrombotic agents in pregnancy

G. F. Gensini, M. Comeglio, R. Abbate

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.

Original languageItalian
Pages (from-to)357-365
Number of pages9
JournalCardiologia
Volume39
Issue number12 Suppl 1
Publication statusPublished - Dec 1994

Fingerprint

Fibrinolytic Agents
Pregnancy
Anticoagulants
Heparin
Aspirin
Coumarins
Antiphospholipid Antibodies
Heart Valves
Therapeutics
Prednisone
Pre-Eclampsia
Atrial Fibrillation
Appointments and Schedules
Fetus
Mothers
Growth

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gensini, G. F., Comeglio, M., & Abbate, R. (1994). I farmaci antitrombotici in gravidanza. Cardiologia, 39(12 Suppl 1), 357-365.

I farmaci antitrombotici in gravidanza. / Gensini, G. F.; Comeglio, M.; Abbate, R.

In: Cardiologia, Vol. 39, No. 12 Suppl 1, 12.1994, p. 357-365.

Research output: Contribution to journalArticle

Gensini, GF, Comeglio, M & Abbate, R 1994, 'I farmaci antitrombotici in gravidanza.', Cardiologia, vol. 39, no. 12 Suppl 1, pp. 357-365.
Gensini GF, Comeglio M, Abbate R. I farmaci antitrombotici in gravidanza. Cardiologia. 1994 Dec;39(12 Suppl 1):357-365.
Gensini, G. F. ; Comeglio, M. ; Abbate, R. / I farmaci antitrombotici in gravidanza. In: Cardiologia. 1994 ; Vol. 39, No. 12 Suppl 1. pp. 357-365.
@article{7e58d2baa48f4a05923379702fc9c410,
title = "I farmaci antitrombotici in gravidanza.",
abstract = "The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.",
author = "Gensini, {G. F.} and M. Comeglio and R. Abbate",
year = "1994",
month = "12",
language = "Italian",
volume = "39",
pages = "357--365",
journal = "Cardiologia (Rome, Italy)",
issn = "0393-1978",
publisher = "Societa Italiana di Cardiologia",
number = "12 Suppl 1",

}

TY - JOUR

T1 - I farmaci antitrombotici in gravidanza.

AU - Gensini, G. F.

AU - Comeglio, M.

AU - Abbate, R.

PY - 1994/12

Y1 - 1994/12

N2 - The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.

AB - The need for antithrombotic therapy during pregnancy is a challenging problem for the clinician. Pregnancy per se is associated with a prothrombotic state, and some conditions definitely require anticoagulant treatment. However, all three main antithrombotic agents (coumarins, heparin and aspirin) have potential serious adverse effects for the mother and fetus. The aim of this review was to discuss the modifications of the coagulation system during pregnancy, and try to properly state the indications and the best schedule of antithrombotic treatment during pregnancy. Presently heparin is considered the anticoagulant of choice for the treatment and prevention of venous thromboembolic disorders and in patients with congenital or acquired thrombophilic conditions. The use of oral anticoagulants is still preferred in women with prosthetic heart valves or atrial fibrillation, but they cannot be administered between the sixth and twelfth week and in the last month of gestation because of the teratogenic and hemorrhagic risks related to their use. Low-dose aspirin is useful for the prevention of pre-eclampsia, intrauterin growth retardation, and in association with heparin or prednisone, for the prevention of abortion in patients with antiphospholipid antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0028716131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028716131&partnerID=8YFLogxK

M3 - Articolo

C2 - 7634297

AN - SCOPUS:0028716131

VL - 39

SP - 357

EP - 365

JO - Cardiologia (Rome, Italy)

JF - Cardiologia (Rome, Italy)

SN - 0393-1978

IS - 12 Suppl 1

ER -